Rhinomed (ASX:RNO) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

RNO Aperçu des actions

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

RNO analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	2/6
Dividendes	0/6

Récompenses

Analyse des risques

Earnings have declined by 8.2% per year over past 5 years

Does not have a meaningful market cap (A$12M)

Negative shareholders equity

Highly volatile share price over the past 3 months

Rhinomed Limited Concurrents

Althea Group Holdings

ASX:AGH

AU$10.2m

Cann Group

ASX:CAN

AU$15.4m

AusCann Group Holdings

ASX:AC8

AU$17.6m

Nyrada

ASX:NYR

AU$10.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Rhinomed
Historique des cours de bourse
Prix actuel de l'action	AU$0.04
Plus haut sur 52 semaines	AU$0.10
Plus bas sur 52 semaines	AU$0.019
Bêta	0.88
1Variation sur 1 mois	60.00%
Variation sur 3 mois	33.33%
Variation sur 1 an	-55.56%
3Variation sur 3 ans	-66.67%
Variation sur 5 ans	-74.19%
Évolution depuis l'introduction en bourse	-99.41%

Nouvelles et mises à jour récentes

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Rendement pour les actionnaires

	RNO	AU Pharmaceuticals	AU Marché
7D	-7.0%	0.9%	2.2%
1Y	-55.6%	52.4%	11.2%

Rendement vs Industrie: RNO underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.

Rendement vs marché: RNO underperformed the Australian Market which returned 9.6% over the past year.

Volatilité des prix

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Average Weekly Movement	26.2%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Cours de l'action stable: RNO's share price has been volatile over the past 3 months.

Volatilité au fil du temps: RNO's weekly volatility has increased from 19% to 26% over the past year.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2004	n/a	Michael Johnson	www.rhinomed.global

Rhinomed Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Rhinomed se comparent-ils à sa capitalisation boursière ?
RNO statistiques fondamentales
Capitalisation boursière	AU$11.51m
Bénéfices(TTM)	-AU$10.91m
Recettes(TTM)	AU$8.05m

1.4x

Ratio P/S

-1.1x

Ratio P/E

Le site RNO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
RNO compte de résultat (TTM)
Recettes	AU$8.05m
Coût des recettes	AU$2.78m
Marge brute	AU$5.28m
Autres dépenses	AU$16.18m
Les revenus	-AU$10.91m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.038
Marge brute	65.53%
Marge bénéficiaire nette	-135.49%
Ratio dettes/capitaux propres	-90.4%

Quelles ont été les performances à long terme de RNO?

Voir les performances historiques et les comparaisons

RNO Aperçu des actions

Récompenses

Analyse des risques

Rhinomed Limited Concurrents

ASX:AGH

AU$10.2m

ASX:CAN

AU$15.4m

ASX:AC8

AU$17.6m

ASX:NYR

AU$10.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Rhinomed Limited Résumé des fondamentaux

1.4x

-1.1x

Bénéfices et recettes